Targovax announced that it has completed the enrollment of the phase 1/2 trial of ONCOS-102 combined with durvalumab in the treatment of patients with advanced colorectal cancer and peritoneal malignancies

Oslo, Norway, June 17, 2021 /PRNewswire/ – Targovax ASA (Or: TRVX)It is a clinical-stage immuno-oncology company that develops immune activators to target difficult-to-treat solid tumors. It announced today that the trials of ONCOS-102 and durvalumab on patients with advanced peritoneal malignancies have completed the recruitment of the colorectal cancer cohort.

This phase 1/2 trial investigated the safety, biology, and safety of ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1) in patients with advanced peritoneal malignancies who had failed previous standard chemotherapy and had histologically confirmed platinum-based therapy. Anti-tumor activity resistant or refractory epithelial ovarian cancer or colorectal cancer.

in October 2020, Reached the pre-defined disease control efficacy threshold in Part 1 of the Colorectal Cancer Cohort, and opened this expanded cohort to recruit Part 2 patients. Clinical and immune activation data is expected to be available in the first half of 2022.

Dr. Magnus Jäderberg, Chief Medical Officer of Targovax said: “We are very pleased to see that the recruitment of this trial has been completed. These patients with metastatic CRC who have failed previous peritoneal metastasis treatments are a large patient population and there are no effective treatments available. We look forward to seeing clinical and immune activation data from this This is a new combination of immunotherapy, and hope that it can bring benefits to patients.”

The trial is between Targovax and AstraZeneca (NASDAQ:AZN), Cancer Research Institute (CRI) and Ludwig Cancer Institute.

For more information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
e-mail: oystein.soug@targovax.com

Renate Berkeley, Investor Relations
Phone: +47 922 61 624
e-mail: renate.birkeli@targovax.com

Media inquiries:
Andreas Tinglun -Corporate Communications (Norway)
Phone: +47 9300 1773
e-mail: andreas.tinglum@corpcom.no

IR inquiry:
Kim Sutton Gorodz -LHA Investor Relations (United States)
e-mail: kgolodetz@lhai.com
Phone: +1 212-838-3777

This information is provided to you by Cision http://news.cision.com

https://news.cision.com/targovax/r/targovax-announces-completed-enrollment-in-the-phase-1-2-trial-with-oncos-102-in-combination-with-du,c3369324

View original content:http://www.prnewswire.com/news-releases/targovax-announces-completed-enrollment-in-the-phase-12-trial-with-oncos-102-in-combination-with-durvalumab-in-patients- with-advanced-colorectal-cancer-with-peritoneal-malignancies-301314392.html

Source Targovax